UK Biotech Learns the Hard Way
This article was originally published in Start Up
Executive Summary
A bunch of UK biotech firms are in trouble, some forced to restructure and others to seek financing on miserably expensive terms. All wish they'd raised more money during the funding bonanza of 2000. Challenging times such as these reveal lingering cracks--and lack of experience--in strategy and business management. This suggests that UK industry, although it has matured significantly since the brutal blow to confidence dealt by a major product failure at British Biotech during the sector's tender early years, still has some way to go.
You may also be interested in...
The Cost-Sharing Solution: The New NICE Ticket
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim?
Biotech Financing Roundup: Where the Money's At
There's a perceived transatlantic divide when it comes to biotechnology financing. European firms, the conventional wisdom goes, lack VC the support of their North American counterparts and thus are at an inherent disadvantage. But an analysis of 2004's VC financing trends shows that on average, European biotechs have pulled in respectable Series A and Series B rounds--later stage financing is another story.
Biotech Financing Roundup: Where the Money's At
There's a perceived transatlantic divide when it comes to biotechnology financing. European firms, the conventional wisdom goes, lack VC the support of their North American counterparts and thus are at an inherent disadvantage. But an analysis of 2004's VC financing trends shows that on average, European biotechs have pulled in respectable Series A and Series B rounds--later stage financing is another story.